Evidence map›Paper›PMID 28764807›Full record

ArticleBreast cancer research : BCR2017

AKT1

Sheheryar Kabraji, Xavier Solé, Ying Huang, Clyde Bango, Michaela Bowden, Aditya Bardia, Dennis Sgroi, Massimo Loda, Sridhar Ramaswamy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. A pre-existing population of ZEB2Journal of experimental & clinical cancer research : CR · 2020
    Article
  15. Review
  16. Article
  17. Review
  18. AKT1NPJ breast cancer · 2019
    Article
  19. Review
  20. AKT1Molecular cancer therapeutics · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sheheryar KabrajiMassachusetts General Hospital Cancer Center, Richard B. Simches Research Building, 185 Cambridge Street, Boston, MA, 02114, USA.
Xavier SoléMassachusetts General Hospital Cancer Center, Richard B. Simches Research Building, 185 Cambridge Street, Boston, MA, 02114, USA.
Ying HuangDana-Farber Cancer Institute, Boston, MA, USA.
Clyde BangoDana-Farber Cancer Institute, Boston, MA, USA.
Michaela BowdenDana-Farber Cancer Institute, Boston, MA, USA.
Aditya BardiaMassachusetts General Hospital Cancer Center, Richard B. Simches Research Building, 185 Cambridge Street, Boston, MA, 02114, USA.
Dennis SgroiMassachusetts General Hospital Cancer Center, Richard B. Simches Research Building, 185 Cambridge Street, Boston, MA, 02114, USA.
Massimo LodaDana-Farber Cancer Institute, Boston, MA, USA.
Sridhar RamaswamyMassachusetts General Hospital Cancer Center, Richard B. Simches Research Building, 185 Cambridge Street, Boston, MA, 02114, USA. sridhar@mgh.harvard.edu.
Dana-Farber Cancer Institute · USMassachusetts General Hospital · USCenter for Cancer Research · US

Funding

(PQC6) Molecular Determinants of Quiescent Cancer CellsR01CA185086 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI VASUDEVAN, SHOBHA · 2014 to 2017
$1.8M
NCI NIH HHS R01 CA185086
6 · The paper itself

Abstract

backgroundAbsence of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) correlates with poor long-term survival in patients with triple negative breast cancer (TNBC). These incomplete treatment responses are likely determined by mechanisms that enable cancer cells to resist being killed. However, the detailed characterization of a drug-resistant cancer cell state in residual TNBC tissue after NACT has remained elusive. AKT1

methodsWe obtained pre-treatment biopsy, post-treatment mastectomy, and metastatic specimens from a retrospective cohort of TNBC patients treated with NACT at Massachusetts General Hospital (n = 25). Using quantitative automated immunofluorescence microscopy, QCCs were identified as AKT

resultsWe showed that QCCs exist as non-random and heterogeneously distributed clusters within primary breast tumors. In addition, these QCC clusters persist after treatment with multi-agent, multi-cycle, neoadjuvant chemotherapy in both residual primary tumors and nodal and distant metastases in patients with triple negative breast cancer.

conclusionsThese first-in-human data potentially qualify AKT1

Indexed as

Neoadjuvant TherapyAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedProto-Oncogene Proteins c-aktTriple Negative Breast NeoplasmsAKT1 protein, humanAntineoplastic AgentsProto-Oncogene Proteins c-aktAKT1low quiescent cancer cellsChemotherapy resistanceQuantitative immunofluorescence microscopy

Identifiers

PMID28764807
PMCPMC5540189
OpenAlexW2741933352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.